Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Trimetazidine or trimetazine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris and vertigo, tinnitus and Ménière's disease. Oral administration in three daily doses.
Since the last update we have not found published data on its excretion in breastmilk.
Its effectiveness is questionable and it has worrisome neurological side effects. European Medicines Agency (EMA) has recommended restricting its use and using it only as a second-line adjunctive therapy. (EMA 2012)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.